Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD

NCT05104216 | Unknown Phase 4

• 1 other identifier: BIBP2021COPD-third dose
• Study Type: interventional
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

Evaluation of immunogenicity, safety and persistence of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease received the third dose of inactivated COVID-19 vaccine .

Conditions

COVID-19; Chronic Bronchitis; COPD

Outcome Measures

Primary Outcomes (4)

• Seroconversion rate

  The rate of seroconversion against coronavirus

  28 days after the 3th dose (Day 28)

• Neutralizing antibody level

  Neutralizing antibody GMT against coronavirus before the 3th dose

  Before the 3th dose (Day 0)

• Neutralizing antibody level

  Neutralizing antibody GMT against coronavirus after the 3th dose

  28 days after the 3th dose (Day 28)

• Neutralizing antibody level

  Neutralizing antibody GMT against coronavirus after the 3th dose

  6 months after the 3th dose

Secondary Outcomes (2)

• Adverse events rate

  0-21days following vaccinations

• Serious adverse event rate

  0-6 months

Study Arms (1)

Experimental Group

EXPERIMENTAL

Subjects receive a third dose of inactivated COVID-19 vaccine

Biological: Inactivated COVID-19 vaccine

Interventions

Inactivated COVID-19 vaccine BIOLOGICAL

receive a third dose of inactivated COVID-19 vaccine

Experimental Group

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects aged 60 and above with full capacity for civil conduct;
• Chronic bronchitis (or chronic obstructive pulmonary disease) diagnosed by a medical institution at level I or above;
• Body temperature \< 37.3 ° C confirmed by clinical examination before enrollment ;
• Able and willing to complete the entire study plan during the study follow-up period;
• Have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol;
• Subjects participating in the past clinical trial have completed two doses of COVID-19 vaccine and blood collection before and after immunization;

You may not qualify if:

• Subjects were previously confirmed cases of COVID-19 or asymptomatic infected persons;
• Being allergic to any component of vaccines (including excipients) ;
• Injection of non-specific immunoglobulin within 1 month before enrollment;
• Injection of live attenuated vaccines within 1 month and injection of other vaccines within 14 days before enrollment;
• Subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angioneurotic edema, dyspnea, etc.);
• Having uncontrolled epilepsy and other progressive neurological disorders and a history of Guillain-Barre syndrome;
• Having severe liver and kidney diseases, malignant tumors, acute diseases or acute episodes of chronic diseases;
• Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukaemia or other autoimmune diseases;
• Have been diagnosed with thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection;
• During an acute episode of chronic bronchitis/chronic obstructive pulmonary disease;
• Subjects who had vaccine-related adverse reactions after the second dose;
• Having high fever (axillary temperature ≥39.0℃) for three days after the second dose of inoculation, or severe allergic reaction;
• Having any adverse nervous system reaction after the second dose;
• During the acute onset of a chronic disease, or the recovery of acute complications less than two weeks;

Sponsors & Collaborators

• China National Biotec Group Company Limited: lead
• Zhejiang Provincial Center for Disease Control and Prevention: collaborator
• Beijing Institute of Biological Products Co Ltd.: collaborator

Study Sites (1)

Zhejiang provincial center for disease control and prevention

Hangzhou, Zhejiang, 310051, China

Location

MeSH Terms

Conditions

COVID-19; Bronchitis, Chronic; Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Bronchitis; Bronchial Diseases; Lung Diseases, Obstructive; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Hanqing He

  Zhejiang Provincial Center for Disease Control and Prevention

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hanqing He

CONTACT

（0571）87115111; hanqinghe@cdc.zj.cn

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Subjects aged ≥60 with chronic bronchitis and COPD who have completed the schedule of two doses for 3 months receive a third dose of inactivated COVID-19 vaccine.

Study Record Dates

• First Submitted: October 21, 2021
• First Posted: November 2, 2021
• Study Start: December 1, 2021
• Primary Completion: June 30, 2022
• Study Completion: June 30, 2022
• Last Updated: November 2, 2021

Record last verified: 2021-10

Locations

CN (1)